---
title: 'A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications
  for prognosis and clinical trial design'
date: '2024-10-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39432026/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241021184321&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: These findings underscore the severe prognostic impact
  of CDKN2A/B deletion in IDH-mutant astrocytomas and highlight the need for further
  refinement of tumor prognostic categorization. Our results provide a key benchmark
  of baseline patient outcomes for therapeutic trials, underscoring the importance
  of CDKN2A/B status assessment, in addition to histologic grading, in clinical trial
  design and therapeutic decision-making for IDH-mutant astrocytoma ...'
disable_comments: true
---
CONCLUSIONS: These findings underscore the severe prognostic impact of CDKN2A/B deletion in IDH-mutant astrocytomas and highlight the need for further refinement of tumor prognostic categorization. Our results provide a key benchmark of baseline patient outcomes for therapeutic trials, underscoring the importance of CDKN2A/B status assessment, in addition to histologic grading, in clinical trial design and therapeutic decision-making for IDH-mutant astrocytoma ...